Retroviral replicating vector–mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity

BACKGROUND. Prodrug-activator gene therapy with Toca 511, a tumor-selective retroviral replicating vector (RRV) encoding yeast cytosine deaminase, is being evaluated in recurrent high-grade glioma patients. Nonlytic retroviral infection leads to permanent integration of RRV into the cancer cell geno...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Hiraoka, Kei, Inagaki, Akihito, Kato, Yuki, Huang, Tiffany T., Mitchell, Leah A., Kamijima, Shuichi, Takahashi, Masamichi, Matsumoto, Hiroshi, Hacke, Katrin, Kruse, Carol A., Ostertag, Derek, Robbins, Joan M., Gruber, Harry E., Jolly, Douglas J., Kasahara, Noriyuki
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Basic and Translational Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5574670/
https://ncbi.nlm.nih.gov/pubmed/28387831
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox038
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados